Peroxisome Proliferator-Activated Receptor (PPAR) Agonists as Promising New Medications for Drug Addiction: Preclinical Evidence

Publisher： Bentham Science Publishers

E-ISSN： 1873-5592|14|7|768-776

ISSN： 1389-4501

Source： Current Drug Targets, Vol.14, Iss.7, 2013-06, pp. : 768-776

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Peroxisome Proliferator-Activated Receptor (PPAR)-α: A Pharmacological Target with a Promising Future

By van Raalte Daniel H.   Li Min   Pritchard P. Haydn   Wasan Kishor M.  

Pharmaceutical Research, Vol. 21, Iss. 9, 2004-09 ,pp. : 1531-1538

Springer Publishing Company

Access to resources Recommend Favorite

Peroxisome Proliferator-Activated Receptor-&ggr; (PPAR-&ggr;) Agonists on Glycemic Control, Lipid Profile and Cardiovascular Risk

By  

Current Molecular Pharmacology, Vol. 5, Iss. 2, 2012-01 ,pp. : 272-281

Bentham Science Publishers

Access to resources Recommend Favorite

Peroxisome Proliferator-Activated Receptor (PPAR) Gamma Agonists as Therapeutic Agents for Cardiovascular Disorders: Focus on Atherosclerosis

By  

Current Pharmaceutical Design, Vol. 23, Iss. 7, 2017-04 ,pp. : 1119-1124

Bentham Science Publishers

Access to resources Recommend Favorite

Enantioselective Synthesis of PPAR (Peroxisome Proliferator-Activated Receptors) Agonists and Antagonists

By  

Current Topics in Medicinal Chemistry, Vol. 14, Iss. 10, 2014-05 ,pp. : 1283-1293

Bentham Science Publishers

Access to resources Recommend Favorite

Agonist of peroxisome proliferator-activated receptor gamma (PPAR-  ): a new compound with potent gastroprotective and ulcer healing properties

By Brzozowski Tomasz  

Inflammopharmacology, Vol. 13, Iss. 1-3, 2005-08 ,pp. : 317-330

VSP

Access to resources Recommend Favorite